Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alize Pharma Launches the First Phase I Clinical Trial for AZP-531

Published: Monday, July 15, 2013
Last Updated: Monday, July 15, 2013
Bookmark and Share
The Medicine and Healthcare Regulatory Authority (MHRA) has granted authorization to conduct a trial in the UK on AZP-531 in healthy volunteers, obese subjects and diabetic patients.

Alize Pharma has announced the launch of the first Phase I clinical trial for AZP-531, its unacylated ghrelin analog, in type 2 diabetes.

The Medicines and Healthcare Regulatory Agency (MHRA), the body that regulates drugs and healthcare products in the UK, has authorized this trial that will be conducted as a combined Phase Ia and Phase Ib protocol.

The clinical trial is set to last approximately 18 months. The objectives will be to assess the safety, determine the pharmacokinetic profile of AZP-531 and to provide preliminary data on AZP-531 metabolic effects, particularly on glycemia.

This double-blind, placebo-controlled trial will be conducted in three parts: a single ascending dose study in healthy volunteers, a 14-day multiple ascending dose study in overweight or obese subjects and a 14-day multiple ascending dose study in type 2 diabetic patients. Up to 112 patients and healthy volunteers will be enrolled in the trial.

“We are very pleased to have reached this development milestone on AZP-531. It is the first unacylated ghrelin analog to enter clinical stage, a program based on an in-depth knowledge of the biology of ghrelin and of its role in the metabolism and metabolic disorders,” said Thierry Abribat, president of Alize Pharma.

Abribat continued, “The results of this first clinical trial will help us to assess the potential of AZP-531 for the treatment of type 2 diabetes. They will also allow initiation of clinical development in other metabolic indications, such as the Prader Willi syndrome and some ischemia-related cardiovascular indications.”

The launch of this clinical program follows five years of collaborative research between Alize Pharma and its academic partners at the Erasmus Medical Center in Rotterdam, in the Netherlands, and the University of Turin, in Italy.

This research has led to the identification of unacylated ghrelin as a new therapeutic class and to the design of AZP-531.

The unique pharmacological profile of AZP-531 differentiates it from ghrelin antagonists and all existing therapeutic classes.

Available preclinical and clinical data suggest that UAG and its analogs improve glycemic control and insulin sensitivity, reduce fat deposition and have a positive effect on vascular remodeling and on recovery following ischemia, through a mechanism involving protection against oxidative stress.

“Following Asparec®, AZP-531 is the second program that we are entering at the clinical stage” said Thierry Abribat. “This emphasizes the expertise in translational medicine of the Alize Pharma team, its capacity to bring innovation to the clinic and thus create value for its shareholders.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Alizé Pharma II Acquired by Jazz Pharmaceuticals
The deal is valued at up to €18 million and did not involve transfer of any employees.
Wednesday, May 11, 2016
Alize Pharma Raises EUR 5 Million (USD 6.6 Million)
The proceeds will finance the clinical development program of AZP-531 (an unacylated ghrelin analog) in Prader-Willi syndrome and type 2 diabetes.
Wednesday, September 10, 2014
Alize Pharma Launches the PREMAG Research Program
This EUR four million collaborative project is aimed at extending the therapeutic potential of AZP-531, Alize Pharma’s unacylated ghrelin analog, to cardioprotection and cachexia.
Friday, January 04, 2013
Alize Pharma Closes EUR 3.3 Million Funding Round
The funds will enable the company to launch clinical development of its UAG (UnAcylated Ghrelin) analog for the treatment of the Prader Willi syndrome and type II diabetes in 2013.
Tuesday, June 05, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!